论文部分内容阅读
目的探讨血清CA125对卵巢上皮性癌的诊断及临床分期的价值。方法选择卵巢上皮性癌住院患者(38例)、卵巢良性肿瘤患者(38例)及卵巢子宫内膜异位囊肿患者(46例),均取空腹静脉血,用电化学发光免疫分析法测定血清CA125水平。结果血清CA125水平在卵巢上皮性癌组显著升高为(974.74±749.66)U/mL,高于卵巢良性肿瘤组的(24.73±19.95)U/mL及卵巢子宫内膜异位囊肿组的(84.05±70.51)U/mL,差异有统计学意义(P<0.05),血清CA125对卵巢上皮性癌的灵敏度为79.55%,特异度为90.63%。卵巢上皮性癌各期的血清CA125水平比较,差异有统计学意义(P<0.05),Ⅰ期最低,Ⅳ期最高。结论血清CA125水平对卵巢上皮性癌的诊断及其临床分期有重要价值。
Objective To investigate the value of serum CA125 in the diagnosis and clinical stage of epithelial ovarian cancer. Methods 38 patients with epithelial ovarian cancer, 38 patients with benign ovarian tumor and 46 patients with ovarian endometriosis were divided into two groups. Fasting venous blood was collected and serum was determined by electrochemiluminescence immunoassay CA125 level. Results Serum CA125 level was significantly higher in epithelial ovarian cancer group (974.74 ± 749.66 U / mL) than that in benign ovarian tumor group (24.73 ± 19.95 U / mL) and ovarian endometriosis group (84.05 ± 70.51) U / mL, the difference was statistically significant (P <0.05). The sensitivity of serum CA125 to epithelial ovarian cancer was 79.55% and the specificity was 90.63%. The serum CA125 levels in all stages of ovarian epithelial carcinoma were significantly different (P <0.05), the lowest in stage Ⅰ and the highest in stage Ⅳ. Conclusion Serum CA125 level has important value in the diagnosis of ovarian epithelial carcinoma and its clinical stage.